ArticleJournal of clinical and experimental hepatology
Diabetes-associated Alterations in the Gut Microbiota-metabolite Profile of NAFLD Under Complex Clinical Conditions.
Article in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) frequently coexists with obesity and type 2 diabetes (T2D), and the presence of these metabolic conditions contributes to substantial heterogeneity in disease progression and metabolic dysfunction. Gut microbiota and their derived metabolites are increasingly recognized as important mediators linking NAFLD with systemic metabolic disorders; however, how overweight and T2D differentially shape gut microbiota-metabolite alterations in NAFLD under complex clinical conditions remains unclear. Methods: In this study, 66 patients with NAFLD (including 27 with T2D) and 26 healthy controls were enrolled. All participants underwent liver ultrasound-based assessment, biochemical testing, and fecal sample collection on the same day. Gut microbiota composition was analyzed using 16S ribosomal RNA gene sequencing, and fecal metabolites, including short-chain fatty acids and bile acids, were quantified using light chromatography-tandem mass spectrometry. Participants were stratified according to overweight and diabetes status to compare microbiota and metabolite profiles across metabolic subgroups. Results: Distinct alterations in gut microbiota and metabolites were observed among NAFLD patients with different metabolic conditions. Patients with T2D showed a butyrate-related pattern in exploratory analysis, including nominally lower butyrate and isobutyrate levels and lower abundance of several butyrate-producing genera, particularly Conclusion: Under complex clinical conditions, overweight and T2D were associated with different gut microbiota profiles and exploratory metabolite patterns in patients with NAFLD, with diabetes showing a stronger association than overweight alone. These exploratory findings highlight the importance of considering metabolic comorbidities when interpreting gut microbiota-metabolite changes in imaging-defined NAFLD and provide preliminary insight into microbial-metabolic patterns underlying disease heterogeneity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.